Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Lisa B LeypoldtBritta BesemerAnne Marie AsemissenMathias HänelIgor Wolfgang BlauMartin GörnerYon-Dschun KoHans Christian ReinhardtPeter StaibChristoph MannRaphael LutzMarkus MunderUllrich GraevenRudolf PecenyHans J SalwenderAnna JauchManola ZagoAxel BennerDiana TichyCarsten BokemeyerHartmut GoldschmidtKatja C WeiselPublished in: Leukemia (2021)